TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The phase III TRIUMPH-2 trial found average weight loss of 11.9% to 18.8% after 80 weeks among adults with obesity and type 2 diabetes taking retatrutide, compared with 5.1% on placebo. The investigational drug also reduced HbA1c, but it is not approved, and the trial did not compare it directly with other weight-loss medicines.
The investigational drug retatrutide was associated with average weight loss of up to 18.8% over 80 weeks in adults with obesity and type 2 diabetes in the phase III TRIUMPH-2 trial, compared with 5.1% among participants given placebo. The findings also showed improved blood-sugar measures; retatrutide is not approved, and the results do not establish how it compares directly with other medicines.
Among 1,152 trial participants, average weight change at week 80 in the treatment-regimen analysis was a loss of 11.9% with the 4-mg dose, 16.8% with 9 mg and 18.8% with 12 mg. Those figures corresponded to average losses of 28.4, 40.3 and 45.6 pounds, respectively. The placebo group lost an average of 5.1%, or 12.8 pounds. These results reflect the specified treatment-regimen estimand, which accounts for events such as stopping treatment or using other weight-loss interventions.
In a separate efficacy estimand, which assumes participants took the assigned medicine as intended and excludes certain intercurrent events, the highest dose was associated with 20.8% average weight loss. That analysis is not the same as the treatment-regimen result and relies on different assumptions. Study presenter Juan P. Frias said more than half of participants in that analysis lost over 15% of their body weight.
Blood-sugar control also improved. Mean HbA1c changes from baseline were a reduction of 1.38 percentage points with 4 mg, 1.50 points with 9 mg and 1.45 points with 12 mg, compared with a 0.45-point reduction on placebo. Up to 40% of retatrutide-treated participants reached an HbA1c below 5.7%, the threshold the report used for normoglycemia. The trial also reported improvements in several cardiometabolic measures, including waist circumference, triglycerides, non-HDL cholesterol and high-sensitivity C-reactive protein.
The double-blind study ran at 92 centers in eight countries. Participants received a once-weekly injection of retatrutide or placebo alongside stable background glucose-lowering treatment. Eligible participants had obesity, type 2 diabetes and a history of trying to lose weight through diet.
Weight Loss Alongside Diabetes Control
The findings address a treatment gap highlighted by the study authors: people with obesity and type 2 diabetes often lose less weight than people without diabetes. The reported results suggest retatrutide may produce substantial weight loss in this population while also improving HbA1c, rather than measuring weight alone.
The treatment-regimen results provide a view of outcomes under the trial’s specified analysis, while the larger figure from the efficacy estimand depends on the assumption that participants followed treatment as intended. Readers should not treat either figure as a direct comparison with other drugs: TRIUMPH-2 had no active-comparator arm. The findings could inform future treatment decisions if the drug is approved, but they do not establish its eventual place in care or its long-term outcomes.
glucose monitoring device for diabetes
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Retatrutide Works in Testing
Retatrutide is an investigational triple agonist that acts on the GIP, GLP-1 and glucagon hormone pathways. Frias, who presented the trial results at the European Association for the Study of Diabetes annual meeting, said engaging these pathways may help explain the weight-loss results. That explanation is the presenter’s interpretation of the findings, not a comparison tested within TRIUMPH-2.
The report compared the study’s results with previously reported weight loss of 13.2% with high-dose semaglutide and 15.7% with tirzepatide in people with diabetes. Those numbers come from other clinical-trial data, not from participants randomized against those medicines in TRIUMPH-2. The source also notes separate EASD-presented data on a combination of eloralintide and tirzepatide; that is a different investigational regimen and trial result.
Retatrutide has drawn attention online, and the report described a gray market for the unapproved drug. That activity does not establish that products sold outside authorized channels are safe or equivalent to the medicine tested in the trial.
“We know that people with type 2 diabetes lose less weight than people without diabetes. We see this irrespective of the weight-loss method, whether it’s pharmacotherapy or metabolic surgery.”
— Juan P. Frias, MD, Los Angeles Institute for Metabolic Research, presenting the findings
weight loss injections for obesity
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Safety and Comparisons Still Open
The trial did not include an active comparator, so it cannot show whether retatrutide is more effective or safer than semaglutide, tirzepatide or other treatments. It also did not collect body-composition data to determine how much weight loss came from fat versus lean mass.
Gastrointestinal effects, especially nausea, diarrhea and constipation, were the most common adverse events. Discontinuation because of gastrointestinal symptoms was reported in 0% to 2% of retatrutide groups and 1% of placebo recipients. Overall, 3% to 11% of participants in retatrutide groups stopped study treatment because of adverse events, compared with 5% on placebo. Hypotension and dysesthesia occurred more often in retatrutide groups.
Seven participants died during the trial; the report said investigators deemed the deaths unrelated to the study interventions. The supplied findings do not provide enough detail to assess the causes of those deaths or answer questions about safety and effectiveness over longer periods. Trial results also cannot establish the quality or safety of unapproved products sold outside clinical studies.
As an affiliate, we earn on qualifying purchases.
Lilly Plans an FDA Submission
Eli Lilly said it plans to submit the retatrutide data to the U.S. Food and Drug Administration in early 2027. The findings therefore do not mean the drug is currently available as an approved treatment. An FDA submission would be a next regulatory step, not a guarantee of approval; the timeline and agency decision remain ahead.
Further evidence will be needed to clarify how retatrutide compares with existing treatments, how its benefits and adverse effects develop over longer follow-up, and what happens to body composition during weight loss. Until regulatory review is complete, the trial results describe an investigational medicine rather than a treatment recommendation.
As an affiliate, we earn on qualifying purchases.
Key Questions
How much weight did participants lose with retatrutide?
At week 80, average weight loss in the treatment-regimen analysis ranged from 11.9% with 4 mg to 18.8% with 12 mg. The placebo group lost 5.1% on average. A separate efficacy analysis reported 20.8% average loss with the highest dose under different assumptions.
Did retatrutide improve blood-sugar control?
Yes. Mean HbA1c fell by 1.38 to 1.50 percentage points in the retatrutide groups, compared with 0.45 points with placebo. Up to 40% of retatrutide-treated participants reached an HbA1c below 5.7%.
Is retatrutide approved for weight loss or diabetes?
No. The source describes retatrutide as investigational. Eli Lilly said it plans to submit data to the FDA in early 2027; that does not mean approval is assured.
How does retatrutide compare with other weight-loss drugs?
TRIUMPH-2 did not compare retatrutide directly with another medicine. The report cites results from separate trials of semaglutide and tirzepatide, but differences between trials mean those figures are not a head-to-head comparison.
What side effects were reported?
The most common adverse events were gastrointestinal, including nausea, diarrhea and constipation. Overall adverse-event-related treatment discontinuation ranged from 3% to 11% in retatrutide groups and was 5% with placebo. Hypotension and dysesthesia occurred more often with retatrutide.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
